Primary Bioscience is betting that single-molecule protein sequencing — not genomics — is the key to making multi-cancer early detection a clinical reality. CEO Stacy Anderson is building the hardware to prove it.
The cancer diagnostics industry has spent the better part of a decade chasing the liquid biopsy dream through the lens of DNA. But inside CoMotion Labs, the University of Washington’s life science incubator in Seattle, a two-person startup is making the case that the real signal has been hiding in plain sight — not in the genome, but in the proteome.
Primary Bioscience is developing a single-molecule protein sequencing device designed to read every protein in a biological sample with the kind of unbiased coverage that today’s mass spectrometry platforms cannot deliver at scale. The premise is direct: proteins are what cells actually do. They encode disease state in real time, reflect post-translational modifications invisible to DNA sequencing, and carry the biomarker signatures that make early, multi-cancer detection theoretically possible — if you can read them precisely enough.
That’s the problem Stacy Anderson, the company’s founder and CEO, has set herself to solve. “CoMotion Labs was instrumental in helping us generate critical early data at a price we could afford,” Anderson said in a statement posted by the incubator. “We’ve found the CoMotion network to be incredibly welcoming and collaborative.”
NANOPORE ARCHITECTURE MEETS PROTEOMICS
Primary Bioscience’s core technology is built on nanopore-based single-molecule sensing — the same fundamental architecture that transformed DNA sequencing when Oxford Nanopore Technologies brought it to market — now reengineered for the far more complex challenge of reading proteins. While DNA sequencing benefits from a four-base alphabet, proteins are composed of twenty amino acids with dramatically varying size, charge, and chemical behavior, making controlled translocation through a nanopore an order of magnitude harder.
The company’s approach as a “comprehensive proteomics platform” — is a deliberate contrast to affinity-based methods like immunoassays or antibody arrays, which can only detect proteins you design a test for. Primary Bioscience’s platform is built to sequence every protein in a sample, including hard-to-detect variants such as single-residue substitutions, splice variants, and post-translational truncations — the molecular ghosts that current clinical assays routinely miss.
“The goal at Primary Bioscience is to make diagnostics proactive rather than reactive.” — Life Science Washington Institute, October 2023
Studies have demonstrated the feasibility of amino acid discrimination and controlled peptide translocation through nanopores — the twin technical hurdles that have historically stalled the field. The theoretical foundation is now solid enough that major instrument players are paying close attention.
Primary Bioscience sits on the hardware side of that frontier — building the device, not just the assay — which positions it closer to a platform company than a point-solution diagnostics startup. That distinction matters enormously for how it will eventually be valued.
WHY PROTEINS, WHY NOW
The liquid biopsy market has been dominated by cell-free DNA approaches, with companies like Guardant Health and GRAIL raising billions on the promise of cancer-signal detection from circulating tumor DNA. The clinical results have been compelling in some cancers, underwhelming in others. The core limitation is intrinsic: ctDNA is sparse, fragmented, and subject to significant noise, particularly in early-stage disease where the tumor burden is lowest and the detection need is highest.
Proteins offer a different signal profile. They are the functional output of gene expression, shaped by alternative splicing and post-translational modification in ways the genome alone cannot predict. A cancer cell’s protein signature can change earlier and more dramatically than its mutational landscape in many cancer types — which is precisely why multi-cancer early detection players have increasingly turned toward proteomics as a complementary or superior modality.
GRAIL’s Galleri test remains the most prominent reference point for multi-cancer early detection at the population level. As of January 2026, GRAIL submitted its Premarket Approval application to the FDA — the test has not yet received FDA approval and has been commercially available as a laboratory-developed test since 2021. Critically, Galleri uses methylation-based analysis of cell-free DNA, not proteomics. Meanwhile, protein-based approaches remain largely research-stage, held back by the throughput and sensitivity limitations of mass spectrometry and the specificity constraints of antibody-based panels. Primary Bioscience is engineering its way around both barriers with a single-molecule, antibody-free architecture.
If the device performs as designed, it would represent a qualitative leap: a sample-agnostic, high-throughput proteomics instrument deployable as both a clinical diagnostic and a research tool.
PIPELINE AND PRODUCT ROADMAP
Primary Bioscience is pre-revenue and operating in deliberate stealth mode. The company is positioned within a device development and platform validation stage — building and iterating on the core hardware before moving toward analytical validation studies required to support regulatory submissions.
The dual-use strategy — deploying the device as both a multi-cancer early detection tool and a research instrument — is a tactically sound approach for an early-stage hardware company. Near-term milestones likely include prototype benchmarking against mass spectrometry gold standards, analytical validation in defined sample matrices, and team expansion ahead of a Series A fundraise. The company graduated from Creative Destruction Lab‘s Vancouver program in 2025, signaling that its scientific and commercial thesis has been reviewed and validated by one of the more rigorous deep-tech accelerator programs in North America. How quickly the company can reach those milestones will determine its fundraising leverage — and its timing in a market that is moving faster than most observers expected.
A CROWDED BUT UNDERDEVELOPED FIELD
The single-molecule protein sequencing space is small but rapidly accelerating. One publicly traded competitor brought a semiconductor chip-based instrument to commercial availability in late 2022 — using time-domain sequencing rather than nanopores, giving it a first-mover advantage in the research market but also a defined set of known performance trade-offs. On the private side, a University of Texas at Austin spin-out has been developing a fluorescence-based readout platform since 2018; it received a $2.2 million grant from the Cancer Prevention and Research Institute of Texas in January 2025 to develop an immuno-oncology diagnostic in collaboration with MD Anderson Cancer Center.
Notably, Oxford Nanopore Technologies — the company that commercialized nanopore DNA sequencing — has not extended its platform to proteins. That gap is meaningful: it suggests the nanopore protein sequencing space remains genuinely open for a purpose-built platform designed from the ground up for proteomics, rather than retrofitted from genomics infrastructure.
These are fundamentally different architectural bets — semiconductor, fluorescence, nanopore — targeting the same market from different angles. Primary Bioscience’s positioning as nanopore-native, single-molecule, and antibody-free occupies a distinct niche from all of them. The question, as with any deep-tech hardware play, is whether the technology can deliver the sensitivity and throughput required for clinical-grade performance. That is the work still in progress.
THE YEAR THE PROTEOMICS RACE HEATS UP
The broader proteomics diagnostics market is entering a critical inflection point. GRAIL’s recent PMA submission for Galleri — the final module filed with the FDA in January 2026 — represents the most significant regulatory moment in multi-cancer early detection since the field emerged. If approved, it will create a reimbursement and commercial pathway that validates the entire category and accelerates investment into complementary and competing technologies.
For Primary Bioscience, 2026 is likely to be a year defined by two parallel imperatives: advancing the core technology toward demonstrable analytical performance milestones, and executing a fundraise that provides the runway to reach device validation. The company’s current seed capitalization of $1.1 million is consistent with pre-prototype-stage hardware companies, but the next phase will require significantly more capital to purchase equipment, build the team, and generate the data packages that institutional investors and strategic partners require.
The question hanging over every single-molecule protein sequencing company is the same: can the device read proteins at the throughput, sensitivity, and accuracy required for clinical applications? The peer-reviewed literature is clear that the physics are plausible. The engineering execution is the hard part.
Anderson has the scientific training to understand where the hard problems are, and the industry experience to know how to build toward solutions. She has assembled early institutional support — IndieBio, CDL, Life Science Washington — that gives the company a credible foundation for what comes next.
In a field that has long promised to move diagnostics from reactive to proactive, Primary Bioscience is one of a small handful of companies working on the hardware layer that could make that shift structurally possible. The science is early. The need is not.